Michael Story, PhD
Dr. is a professor at the University of Texas (UT) Southwestern Medical Center, Dallas. Dr. Story earned his PhD from Colorado State University. He holds the David A. Pistenmaa, MD, PhD Distinguished Chair in Radiation Oncology, serves as Vice-Chair of the Department of Radiation Oncology, Chief of the Section of Molecular Radiation Biology, and Director of the Pre-clinical Radiation Core Facility. Dr. Story serves on the editorial board of Mutagenesis, Scientific Reports, Translational Cancer Research and the Publications Committee of the Congress of Space Research (COSPAR). Dr. Story is a member of the Scientific Program sub-Committee and Executive Committee of the Particle Therapy Cooperative Group (PTCOG). Dr. Story is also a member of the Board of Directors of the National Council of Radiation Protection and Measurement.
Dr. Story directs the radiobiology course for the Medical Physics graduate program and the Radiation Oncology medical resident program and is a faculty member for NASA’s Space Radiation Health School. Dr. Story's research is focused on five areas associated with radiation exposure: (1) delineating the effects of novel superoxide dismutase compounds that can act as both radioprotector and radiosensitizer in the same setting; (2) understanding and exploiting the biological effects of tumor treating fields in combination with radiation and/or chemotherapy agents; (3) developing biomarkers of the radioresponse of lung and liver tissues to high linear-energy transfer radiation exposures, including the development of biomarkers of carcinogenic risk; (4) enhancement of carbon ion radiotherapy for pancreatic and head and neck cancers; and (5) identification of genomic or epigenomic factors that predict or are prognostic for the radioresponse in head and neck squamous cell carcinoma. Dr. Story's research is funded by the NCI, NASA, the Cancer Prevention and Research Institute of Texas, and industry.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NovocureTopic:tumor treating fieldsDate added:09/28/2022Date updated:09/28/2022Relationship end date:06/30/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Galera TherapeuticsTopic:radioprotection/sensitizationDate added:09/28/2022Date updated:09/28/2022Relationship end date:12/31/2023
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.